You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 22, 2025

Kai Pharms Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Kai Pharms Inc
International Patents:90
US Patents:8
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Kai Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-003 Feb 7, 2017 RX Yes Yes 10,344,765 ⤷  Try for Free Y ⤷  Try for Free
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-002 Feb 7, 2017 RX Yes Yes 8,377,880 ⤷  Try for Free Y Y ⤷  Try for Free
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-001 Feb 7, 2017 RX Yes Yes 10,344,765 ⤷  Try for Free Y ⤷  Try for Free
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-003 Feb 7, 2017 RX Yes Yes 9,701,712 ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Kai Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2459208 CR 2017 00006 Denmark ⤷  Try for Free PRODUCT NAME: ETELCALCETID ELLER ET SALT DERAF, INKLUSIV ETELCALCETIDHYDROCHLORID; REG. NO/DATE: EU/1/16/1142/001-012 20161115
2459208 C20170006 00208 Estonia ⤷  Try for Free PRODUCT NAME: ETELKALTSETIID;REG NO/DATE: EU/1/16/1142 15.11.2016
2459208 2017/011 Ireland ⤷  Try for Free PRODUCT NAME: ETELCALCETIDE, OR A SALT THEREOF, INCLUDING ETELCALCETIDE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1142/001-012 20161111
2459208 8/2017 Austria ⤷  Try for Free PRODUCT NAME: ETELCALCETID ODER EIN SALZ DAVON EINSCHLIESSLICH ETELCALCETID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1142 (MITTEILUNG) 20161115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: KAI Pharmaceuticals Inc - Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, understanding the competitive landscape is crucial for success. Today, we'll dive deep into KAI Pharmaceuticals Inc., exploring its market position, strengths, and strategic insights that have shaped its journey in the industry.

The Rise of KAI Pharmaceuticals

KAI Pharmaceuticals, a privately held pharmaceutical company, has made significant strides in the development of novel therapies for chronic kidney disease (CKD). Founded with a mission to address unmet medical needs, KAI has quickly become a notable player in the pharmaceutical arena[1].

A Focused Approach

KAI's primary focus has been on developing innovative treatments for secondary hyperparathyroidism (SHPT) in patients with CKD who are on dialysis. This targeted approach has allowed the company to concentrate its resources and expertise on a specific area of high unmet need[1].

KAI's Crown Jewel: KAI-4169

At the heart of KAI's portfolio lies KAI-4169, a novel peptide agonist of the calcium sensing receptor (CaSR). This innovative drug candidate has shown promising results in clinical trials, positioning KAI as a potential leader in SHPT treatment[1].

Mechanism of Action

KAI-4169 works by modulating the release of parathyroid hormone (PTH), a key factor in calcium homeostasis. This unique mechanism of action sets it apart from existing treatments and has garnered significant attention from the medical community[1].

Clinical Success

"Phase 2a data demonstrated that administration of KAI-4169 resulted in sustained reductions in PTH, phosphorus, calcium and FGF-23, recognized markers of SHPT."[9]

These encouraging results have not only validated KAI's approach but also positioned KAI-4169 as a potential game-changer in SHPT treatment.

Market Position and Competitive Advantage

KAI Pharmaceuticals has carved out a unique position in the pharmaceutical landscape, focusing on an area with significant unmet need. This strategic focus has allowed the company to build expertise and gain a competitive edge in the SHPT market.

Addressing a Large Market

With approximately 1,644,000 CKD patients on dialysis in developed countries, KAI is targeting a substantial market[9]. The prevalence of SHPT in this population further underscores the potential impact of KAI's therapies.

Innovative Delivery Method

KAI-4169's intravenous administration during dialysis represents an innovative approach to treatment. This method could potentially improve patient compliance and treatment efficacy, setting KAI apart from competitors[9].

Strategic Partnerships and Acquisitions

KAI's promising pipeline and strategic focus have not gone unnoticed in the industry. In a significant move, Amgen, a leader in biotechnology, announced its acquisition of KAI Pharmaceuticals in 2012[1].

The Amgen Acquisition

Amgen's decision to acquire KAI for $315 million in cash speaks volumes about the potential of KAI-4169 and the company's overall strategic value[1]. This acquisition has provided KAI with the resources and expertise of a global pharmaceutical giant, potentially accelerating the development and commercialization of its therapies.

"Amgen is ideally positioned to bring KAI-4169 to market and to patients, given the company's decades of experience in developing and delivering therapies for patients with chronic kidney disease."[9] - Steve James, President and CEO of KAI

Strengths and Core Competencies

KAI Pharmaceuticals' success can be attributed to several key strengths and core competencies:

1. Focused Research and Development

By concentrating on SHPT in CKD patients, KAI has developed deep expertise in this area. This focused approach has allowed for efficient resource allocation and rapid progress in drug development[1].

2. Innovative Drug Design

The development of KAI-4169, with its novel mechanism of action, demonstrates KAI's capability in innovative drug design. This strength positions the company as a potential leader in next-generation SHPT treatments[1].

3. Strong Clinical Results

The positive Phase 2a results for KAI-4169 highlight KAI's ability to translate scientific concepts into clinically effective therapies. This track record of clinical success enhances the company's credibility and market position[9].

4. Strategic Partnerships

KAI's partnership with Ono Pharmaceutical for Japanese rights to KAI-4169 showcases the company's ability to form strategic alliances. These partnerships can provide additional resources and expand market reach[1].

Challenges and Market Dynamics

Despite its strengths, KAI Pharmaceuticals operates in a challenging and competitive environment. Understanding these challenges is crucial for assessing the company's long-term prospects.

Regulatory Hurdles

The pharmaceutical industry is heavily regulated, and navigating the approval process for new drugs can be time-consuming and costly. KAI must successfully navigate these regulatory challenges to bring KAI-4169 to market.

Competition in SHPT Treatment

While KAI-4169 shows promise, it enters a market with existing treatments for SHPT. Competing with established therapies and differentiating its product will be crucial for KAI's success.

Dependence on Key Product

With KAI-4169 as its primary drug candidate, KAI's success is heavily dependent on this single product. Diversifying its pipeline could help mitigate risks associated with this dependence.

Strategic Insights and Future Outlook

Based on the analysis of KAI Pharmaceuticals' market position and strengths, several strategic insights emerge:

1. Leveraging Amgen's Resources

The acquisition by Amgen provides KAI with significant resources and expertise. Leveraging these assets effectively could accelerate the development and commercialization of KAI-4169.

2. Expanding Indications

While initially focused on SHPT in CKD patients on dialysis, exploring additional indications for KAI-4169 could expand its market potential. The company's preclinical research on prehemodialysis applications is a step in this direction[1].

3. Continued Innovation

KAI's success with KAI-4169 demonstrates its innovative capabilities. Continuing to invest in research and development could lead to the discovery of additional novel therapies, strengthening the company's pipeline.

4. Global Expansion

The partnership with Ono Pharmaceutical for Japanese rights to KAI-4169 highlights the potential for global expansion. Exploring similar partnerships in other key markets could increase KAI's global footprint.

The Broader Impact on Chronic Kidney Disease Treatment

KAI Pharmaceuticals' work in SHPT treatment has implications beyond the company itself. It represents a step forward in addressing the complex needs of CKD patients.

Improving Patient Outcomes

If successful, KAI-4169 could significantly improve the quality of life for CKD patients on dialysis. The potential for sustained reductions in key SHPT markers could lead to better long-term outcomes for these patients[9].

Advancing the Field

KAI's innovative approach to SHPT treatment could inspire further research and development in the field of CKD. This could lead to a new wave of therapies addressing various aspects of this complex disease.

Key Takeaways

  • KAI Pharmaceuticals has established a strong position in the SHPT treatment market through its innovative drug candidate, KAI-4169.
  • The company's focused approach and strong clinical results have attracted significant industry attention, culminating in its acquisition by Amgen.
  • KAI's strengths lie in its focused R&D, innovative drug design, and ability to form strategic partnerships.
  • Challenges include regulatory hurdles, market competition, and dependence on a key product.
  • Future strategies could involve leveraging Amgen's resources, expanding indications, continued innovation, and global expansion.
  • KAI's work has the potential to significantly impact CKD treatment, improving patient outcomes and advancing the field.

FAQs

  1. What is KAI Pharmaceuticals' main focus? KAI Pharmaceuticals primarily focuses on developing treatments for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis.

  2. What is KAI-4169? KAI-4169 is a novel peptide agonist of the calcium sensing receptor (CaSR) developed by KAI Pharmaceuticals for the treatment of SHPT in CKD patients on dialysis.

  3. Who acquired KAI Pharmaceuticals and when? Amgen acquired KAI Pharmaceuticals in 2012 for $315 million in cash.

  4. What were the key findings from KAI-4169's Phase 2a clinical trials? Phase 2a trials showed that KAI-4169 resulted in sustained reductions in PTH, phosphorus, calcium, and FGF-23, which are recognized markers of SHPT.

  5. How does KAI-4169 differ from existing SHPT treatments? KAI-4169 is administered intravenously during dialysis, which could potentially improve patient compliance and treatment efficacy compared to existing treatments.

Sources cited:

  1. https://www.genengnews.com/news/amgen-to-pick-up-peptide-drug-firm-kai-pharmaceuticals-for-315m/
  2. https://investors.amgen.com/news-releases/news-release-details/amgen-acquire-privately-held-kai-pharmaceuticals

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.